Pilot Study: Effects of Nimodipine on Alcohol Drinking (NCT06900998) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Pilot Study: Effects of Nimodipine on Alcohol Drinking
United States5 participantsStarted 2026-09-01
Plain-language summary
This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).
Who can participate
Age range21 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies).
✓. Ability to read English at 6th grade level or higher.
✓. Meet DSM-V criteria for at least moderate AUD.
✓. Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the alcohol drinking paradigm (ADP).
Exclusion criteria
✕. Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months.
✕. Meet current DSM-V criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder.
✕. Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines, and barbiturates.
✕. Psychotic or other severe psychiatric disorders as determined by clinical evaluation.
✕. Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months.
✕. Medical conditions that would contraindicate the consumption of alcohol or use of nimodipine including untreated or not adequately controlled hypertension or hypotension. Blood pressure at or below 100/65 will be exclusionary.
✕. Heart rate of less than 50 bpm.
✕. Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) \>3 times upper limit of normal (ULN); alanine aminotransferase (ALT) \> 3 times ULN; total bilirubin \>1.5 times ULN; serum creatinine \>2.0 times ULN.